<DOC>
	<DOC>NCT00402363</DOC>
	<brief_summary>The purpose of this study is to evaluate efficacy and safety of Omacor (omega-3-acid ethyl esters) in patients with recurrent, symptomatic atrial fibrillation.</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Men and women age 18 years or older History of symptomatic atrial fibrillation (either paroxysmal or persistent) Provide written informed consent and authorization for protected health information disclosure Permanent (chronic) atrial fibrillation Antiarrhythmic drug therapy which cannot be stopped Use of amiodarone with prior 6 months History of unsuccessful cardioversion History of certain cardiovascular conditions or cardiac surgery within prior 6 months History of stroke within prior 6 months Implanted cardiodefibrillator Certain circulatory, thyroid, pulmonary, liver, kidney, musculoskeletal or metabolic conditions, or cancer (except nonmelanoma skin cancer) Poorly controlled diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Lovaza</keyword>
	<keyword>Omega-3 fatty acids</keyword>
	<keyword>Omacor</keyword>
	<keyword>Paroxysmal atrial fibrillation</keyword>
</DOC>